Pharvaris PHVS
NASDAQ PHVS
$35.25 -0.41 (-1.15%)
As of: Sep 4, 2026 · 3:59 PM EDT

Pharvaris (PHVS) Accounts Payables (2019 - 2026)

Pharvaris' (PHVS) quarterly Accounts Payables came in at $3.2 million in Q1 2026, down 28.63% YoY from $4.4 million in Q1 2025, and down 46.71% on a QoQ basis from $6.0 million in Q4 2025.

Analysis

Pharvaris (PHVS) Accounts Payables (2019 - 2026) Analysis & Trends

Pharvaris (PHVS) has 8 years of Accounts Payables data on file, last reported at $3.2 million in Q1 2026.

  • Quarterly Accounts Payables fell 28.63% year-over-year to $3.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.2 million (down 28.63% YoY) and the FY2025 annual result came in at $5.8 million, up 17.0% from the prior year.
  • Accounts Payables retreated to $3.2 million in Q1 2026, from $6.0 million in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $8.6 million in Q1 2023 to a low of $3.0 million in Q3 2025.
  • A 5-year average of $5.0 million and a median of $4.8 million in 2023 frame the typical range for Accounts Payables.
  • Annual changes were most pronounced in 2022 — Accounts Payables jumped 139.39% — and 2023, when it sank 54.1%.
  • Tracing PHVS's Accounts Payables over 5 years: stood at $6.8 million in 2022, then slumped by 54.1% to $3.1 million in 2023, then jumped by 55.75% to $4.9 million in 2024, then advanced by 22.09% to $6.0 million in 2025, then slumped by 46.71% to $3.2 million in 2026.
  • The last three Accounts Payables figures came in at $3.2 million (Q1 2026), $6.0 million (Q4 2025), and $3.0 million (Q3 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Accounts Payables (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn 429.50 Mn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 1.16 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn 1.52 Bn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn 167.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn - 88.42 Mn
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 470.30 Mn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 108.02 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn - 35.57 Mn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 428.93 Mn
10 Pharvaris 2.10 Bn 1.73 Bn 85,072.10 3,247.29 Bn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 3,247.29 Bn
Mar 31, 2026 3,172.53 Bn
Dec 31, 2025 5,953.14 Bn
Sep 30, 2025 2.98 Mn
Jun 30, 2025 5.50 Mn
Mar 31, 2025 4.45 Mn
Dec 31, 2024 4,875.89 Bn
Sep 30, 2024 4.61 Mn
Jun 30, 2024 3.20 Mn
Mar 31, 2024 6.04 Mn
Dec 31, 2023 3,130.69 Bn
Sep 30, 2023 4.83 Mn
Jun 30, 2023 5,746.92 Bn
Mar 31, 2023 8.62 Mn
Dec 31, 2022 6,820.44 Bn
Sep 30, 2022 7.15 Mn
Jun 30, 2022 4.45 Mn
Mar 31, 2022 3.77 Mn
Dec 31, 2021 2,849.14 Bn
Sep 30, 2021 4.54 Mn